Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Document first published:: 9 July 2020
Page updated:: 22 July 2020
Topic:: Commissioning, Medicine, Specialised commissioning
Publication type:: Policy or strategy, Report

Document

$Clinical commissioning policy: Ustekinumab for refractory Crohn’s disease in pre-pubescent children$

Clinical commissioning policy: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

PDF
105 KB
9 pages

Document

$Clinical panel report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children$

Clinical panel report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

PDF
23 KB
2 pages

Document

$CPAG summary report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children$

CPAG summary report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

PDF
124 KB
8 pages

Document

$Evidence report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children$

Evidence report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

PDF
21 KB
2 pages

Document

$Evidence review: Ustekinumab for refractory Crohn’s disease in pre-pubescent children$

Evidence review: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

PDF
547 KB
35 pages

Document

$Public consultation report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children$

Public consultation report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

PDF
32 KB
2 pages

Document

$Engagement report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children$

Engagement report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

PDF
37 KB
3 pages